Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109309 | 0.84 | KDM1A (0.38) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7110631 | 0.84 | ALDH1A1 (0.35) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7110629 | 0.82 | ALDH1A1 (0.40) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7110957 | 0.75 | RORC (0.31) | RORCNPY1R | |
| SCHEMBL7112812 | 0.71 | HDAC3 (0.33) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7110961 | 0.71 | HDAC3 (0.33) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7569169 | 0.70 | RAB9A (0.38) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM1A | |
| SCHEMBL6254095 | 0.69 | KDM1A (0.49) | ALDH1A1MAPTRAB9AKDM1AL3MBTL1 | |
| SCHEMBL6254097 | 0.69 | KDM1A (0.49) | ALDH1A1MAPTRAB9AKDM1AL3MBTL1 | |
| SCHEMBL10271980 | 0.69 | KDM1A (0.44) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299103-A1 | 4,5-DIHYDRO-THIAZO-2-YLAMINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | Aventis Pharma S.A. (FR) | 2003-04-09 | — | — | EP | claimed |
| WO-2001093867-A1 | 4,5-DIHYDRO-THIAZO-2-YLAMINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2001-12-13 | — | — | WO | claimed |
| EP-1299103-A1 | 4,5-DIHYDRO-THIAZO-2-YLAMINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | Aventis Pharma S.A. (FR) | 2003-04-09 | — | — | EP | disclosed |
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| WO-2001093867-A1 | 4,5-DIHYDRO-THIAZO-2-YLAMINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | ALK, QDPR, CYP3A7 | ALDH1A1 22/4885MAPT 2212/4885NPC1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.